Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
← catalyst calendarNCT07747506 · readout in 347 d
Sponsored by Verastem, Inc. (industry) · VSTM — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
2estimated
Sites
2
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-03 | estimated | When the study began enrolling |
| Primary completion | 2027-08-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Low Grade Ovarian Serous Adenocarcinoma
- Ovarian Cancer
Intervention
- Drug: avutometinib + defactininb combination — also filed as avutometinib (VS-6766) and defactinib (VS-6063)
Primary outcome
what the primary-completion date above is the date OFDuration of Treatment Exposure to Avutometinib in Combination With Defactinib
measured Until treatment discontinuation (approximately 20 months)
Permalink · VSTM's whole pipeline · Catalyst calendar · Every registered study · What changed